Differences in actionable genomic alterations between brain metastases and non‑brain metastases in patients with non‑small cell lung cancer

Differences in actionable genomic alterations between brain metastases and non‑brain metastases in patients with non‑small cell lung cancer

Brain metastases (BM) have been closely associated with increased morbidity and poor survival outcomes in patients with non‑small cell lung cancer (NSCLC). Excluding risk factors in histological subtypes, genomic alterations, including epidermal growth factor receptor mutations and anaplastic lympho...

Full description

Bibliographic Details
Main Authors: Hou, W. (Author), Jiang, H. (Author), Jiang, L. (Author), Li, W. (Author), Lou, J. (Author), Lv, P. (Author), Ma, J. (Author), Nian, R. (Author), Wang, Y. (Author), Wu, S. (Author), Xu, Y. (Author), Zhang, H. (Author), Zhao, J. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
brain metastases
circulating tumor deoxyribonucleic acid
non‑small cell lung cancer
somatic mutations
tissue
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items